Ondansan (Ondansetron)

Ondansetron, the active ingredient in Ondansan, is a 5‑HT3 receptor antagonist presented as an oral tablet for oral use. It is employed to prevent and treat nausea and vomiting caused by chemotherapy, radiotherapy, and postoperative recovery in adult patients.

GNH USA supplies Ondansan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, ensuring consistent quality and regulatory compliance for global distribution. The company adheres to EU GMP standards and provides reliable logistics for timely delivery to clinical sites.

Ondansan, a 5‑HT3 receptor antagonist, is indicated for several types of nausea and vomiting. - Chemotherapy‑induced nausea and vomiting: helps prevent and control nausea and vomiting in patients undergoing cancer chemotherapy. - Radiotherapy‑induced nausea and vomiting: reduces the frequency of nausea and vomiting associated with radiation treatment. - Postoperative nausea and vomiting: used to lessen nausea and vomiting after surgical procedures.

Ondansan may cause a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Headache: mild to moderate pain in the head. - Constipation: reduced bowel movements or hard stools. - Diarrhoea: loose, watery stools. - Fatigue: feeling unusually tired or weak.

Serious or Rare Side Effects: - QT interval prolongation: potential heart rhythm disturbance. - Severe allergic reaction: rash, swelling, or difficulty breathing. - Serotonin syndrome: rare but serious condition when combined with other serotonergic agents.

Before using Ondansan, consider the following precautions. - Renal impairment: dose adjustment may be required in patients with severe kidney dysfunction. - Hepatic impairment: monitor liver function and adjust dose if necessary. - Concomitant QT‑prolonging drugs: avoid or monitor closely due to risk of cardiac arrhythmia. - Electrolyte disturbances: correct low potassium or magnesium levels to reduce cardiac risk. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Ondansan can interact with other medicines; awareness of the interaction level is important.

Major Interactions (Avoid): - Apomorphine: can cause profound hypotension and loss of consciousness. - Certain antiarrhythmic agents (e.g., amiodarone, quinidine): may markedly increase QT prolongation risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise ondansetron plasma levels. - CYP2D6 substrates (e.g., tramadol, codeine): potential for altered metabolism. - Other serotonergic drugs (e.g., SSRIs, tramadol): monitor for signs of serotonin syndrome.